The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.
Biotherapies in large vessel vasculitis / Pazzola, G; Muratore, Francesco; Pipitone, N; Salvarani, Carlo. - In: REVUE DE MEDECINE INTERNE. - ISSN 0248-8663. - 37:4(2016), pp. 274-278. [10.1016/j.revmed.2015.08.012]
Biotherapies in large vessel vasculitis
MURATORE, Francesco;SALVARANI, CARLO
2016-01-01
Abstract
The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0248866315006347-main.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
596.79 kB
Formato
Adobe PDF
|
596.79 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
